News Daily News Year in Review: Tirzepatide, Finerenone, and Digitoxin Score Big in Heart Failure Michael O'Riordan December 30, 2025
News Daily News Benefits of Various SGLT2 Inhibitors Mostly Consistent in Observational Study Michael O'Riordan January 22, 2025
News Conference News THT 2024 Debating the Role of T-TEER in the Sickest Patients Michael O'Riordan March 05, 2024
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Daily News Takotsubo Trigger Type Matters, With Physical Shocks Linked to Worse Outcomes Shelley Wood July 19, 2023
News Daily News Poor Outcomes in HF Patients With Moderate Aortic Stenosis: Observational Data Michael O'Riordan March 29, 2023
News Conference News ACC 2023 How Dapagliflozin Works in HFpEF: Some Clues From CAMEO-DAPA Todd Neale March 09, 2023
News Conference News ACC 2022 New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More Shelley Wood April 01, 2022
News Conference News ACC 2021 Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF Michael O'Riordan May 25, 2021
News Daily News Don’t Overlook COVID-19’s Cardiovascular Footprint, Say NYC Physicians Caitlin E. Cox April 09, 2020
News Conference News ESC Congress 2011: Drugs, Devices Work Together Caitlin E. Cox September 06, 2011